Investment and money
Apple's China syndrome

Aggressive growth stock pick: HSN

Don't fight the 'fiscal slice'

Top picks 2013: Susser Petroleum

B of A inks whopping $10 billion mortgage settlement

Wendy's hikes prices: Here come falling sales

7 hot tech stocks to watch in 2013

Investing in breakfast stocks

Precious opportunities for traders

Google starts the year with a big win

Discover launches new no-fee credit card

Statoil expands its global reach

Top picks 2013: Oakmark Int'l, Matthews Asian

Top picks 2013: Gladstone Commercial

Inside Wall Street: CVS for your 2013 portfolio

Peregrine Pharma soars 80% on study review

Network stocks: 2 buys, 2 sells

Research In Motion is still doomed

Target targets showrooming shoppers

Top picks 2013: Triumph

Will big bank stocks keep up their big run in 2013?

Alcoa is shining brighter

Can HBO compete with Netflix?

Credit Suisse says Bank of America overvalued

Retailers face spending slowdown

Peregrine Pharma soars 80% on study review
Small-cap biotech company Peregrine Pharmaceuticals (PPHM -0.05%) was the leading gainer on the Nasdaq on Monday after it updated investors on data problems with its Phase II clinical trial of its lead cancer drug bavituximab.

The stock closed Monday up 80% to $2.43. Shares gapped higher at the open and continued to climb throughout the day, posting an intraday high of $2.55. Volume was extremely heavy at around 62.6 million shares, which compares to a three-month daily average of under 4 million.

Peregrine shares have been on a wild ride the past six months. The stock had risen from $0.50 in mid-June to a high of $5.37 on September 21 due to promising overall survival data from the company's randomized Phase II trial of bavituximab to treat second-line non-small cell lung cancer. The results, Peregrine initially said, showed "a doubling of overall survival."

On Sept. 24, however, the company revealed discrepancies it had uncovered in the trial. Peregrine said in a statement that "it discovered major discrepancies between some patient sample test results and patient treatment code assignments." The company therefore recommended investors do not rely on any of the clinical data from the trial that were presented earlier. Investors, who were fearful that the trial would be completely invalidated, hammered Peregrine shares back under $1.00.

However, according to Peregrine's most recent update, this is apparently not the case. The company said Monday that the data problems are limited to the 1 milligram dose of bavituximab. After conducting a review of testing procedures at various trial sites, Peregrine said that there is no evidence that the problems affected the results of the 3 milligram treatment. Furthermore, that study showed that patients lived an average of 13 months after beginning treatment, or twice as long as patients who were not treated with the drug and received only chemotherapy in the clinical trial.

In the wake of the update from Peregrine, which vindicates the results of the 3 milligram arm of the drug trial, Roth Capital Partners analyst Joseph Pantginis upgraded the stock to "buy" from "neutral." In a client note, Pantginis said, "We believe this is a major step forward for Peregrine in getting bavi back on track, though the company is still faced with a bit of an uphill battle." Due to the data problems, Pantginis added that the study results will "still be viewed as 'tainted,' representing a key risk, though we believe the 3 milligram arm data remains impressive."

Over the last six months, Peregrine Pharmaceuticals has been unbelievably volatile. Investors and traders involved in this name have been given numerous opportunities to either make or lose vast sums of money. In fact, many have probably done both at different times. After Monday's big rally, Peregrine is trading around $2 above its 52-week low and $3 below its 52-week high.

At current levels, PPHM is sitting at its best levels since its nearly 80% plunge on September 24. In light of Monday's good news, there is certainly the possibility of more upside in the stock, but investors should expect continued volatility going forward as the outlook for bavituximab remains murky.

Для печати
MGM gets nod for second casino in Macau

Facebook's announcement no big deal

Market trends show stunning flip-flops

An aggressive bet on pollution control

Hewlett-Packard: The Dow's top underdog

Buffett should reconsider Goldman Sachs

Apple gets price target, estimate cut

Less is still more for US restaurant chains

Boeing hopes to fly above 787 safety storm

Can Dell save itself by going private?

We could be in for a year of M&A

Play the housing rebound with this stock

The best commodity play: Plain Jane ETFs

Earnings season off to a superb start

Herbalife: Battle of the hedge funds

Ford doubles dividend - is it now an income stock?

Face time with Mark Zuckerberg?

Whole Foods should buy Trader Joe's

Is fee pressure latest threat to 'old' network TV model?

Why Wal-Mart could be an $80 stock

Uncertainty looms large as earnings season starts

Boeing shares slip as FAA review of 787 begins

Is Bill Ackman's Pershing Square toast?

4 stocks shining in the Oscar spotlight

Volcano, St. Jude: 2 hearts beat as one

Bowling, billiards, boating make Brunswick a buy

MGM sees progress on Macau casino

Glaxo to enter packed field of diabetes drugs

The new Corvette Stingray: Worth the wait?

It's time to eat some crow

Johnson Controls to benefit from start-stop batteries

Citi Trends upgraded to 'outperform'

When Apple falls, these 3 fall with it

Can Michael Dell save his struggling PC empire?

Car dealer stocks: Kick the tires carefully

Investors welcome China's market moves

Inside Wall Street: Noble expands offshore drilling

Is Hewlett-Packard stock a bargain or a landmine?